构建与 RFC5 免疫相关基因相关的宫颈癌患者预后签名。
Construction of a prognostic signature of RFC5 immune-related genes in patients with cervical cancer.
机构信息
School of Clinical Medicine, Dali University, Dali, Yunnan, China.
Xichang People's Hospital, Xichang, Sichuan, China.
出版信息
Cancer Biomark. 2023;37(4):261-277. doi: 10.3233/CBM-220347.
BACKGROUND
Cervical cancer (CC) is a malignant tumor threatening women's health. Replication factor C (RFC) 5 is significantly highly expressed in CC tissues, and the immune microenvironment plays a crucial role in tumor initiation, progression, and metastasis.
OBJECTIVE
To determine the prognostic role of RFC5 in CC, analyze the immune genes significantly associated with RFC5, and establish a nomogram to evaluate the prognosis of patients with CC.
METHODS
High RFC5 expression in patients with CC was analyzed and verified through TCGA GEO, TIMER2.0, and HPA databases. A risk score model was constructed using RFC5-related immune genes identified using R packages. Combining the risk score model and clinical information of patients with CC, a nomogram was constructed to evaluate the prognosis of patients with CC.
RESULTS
Comprehensive analysis showed that the risk score was a prognostic factor for CC. The nomogram could predict the 3-year overall survival of patients with CC.
CONCLUSIONS
RFC5 was validated as a biomarker for CC. The RFC5 related immune genes were used to establish a new prognostic model of CC.
背景
宫颈癌（CC）是一种威胁女性健康的恶性肿瘤。复制因子 C（RFC）5 在 CC 组织中表达显著升高，免疫微环境在肿瘤的发生、发展和转移中起着至关重要的作用。
目的
确定 RFC5 在 CC 中的预后作用，分析与 RFC5 显著相关的免疫基因，并建立列线图来评估 CC 患者的预后。
方法
通过 TCGA GEO、TIMER2.0 和 HPA 数据库分析和验证 CC 患者中高 RFC5 表达。使用 R 包识别与 RFC5 相关的免疫基因，构建风险评分模型。结合 CC 患者的风险评分模型和临床信息，构建列线图来评估 CC 患者的预后。
结果
综合分析表明，风险评分是 CC 的一个预后因素。该列线图可以预测 CC 患者的 3 年总生存率。
结论
RFC5 被验证为 CC 的生物标志物。利用 RFC5 相关免疫基因建立了 CC 的新预后模型。
Zotero 插件